SEPN Stock Summary and Trading Ideas (Septerna | NASDAQ:SEPN)

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Septerna trades on the NASDAQ stock market under the symbol SEPN.

As of June 12, 2026, SEPN stock price climbed to $35.95 with 462,691 million shares trading.

SEPN has a beta of 0.65, meaning it tends to be less sensitive to market movements. SEPN has a correlation of 0.02 to the broad based SPY ETF.

SEPN has a market cap of $1.62 billion. This is considered a Small Cap stock.

Last quarter Septerna reported $27 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.13.

The top ETF exchange traded funds that SEPN belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.

SEPN has outperformed the market in the last year with a price return of +245.3% while the SPY ETF gained +24.1%. SEPN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +35.9% and +19.0%, respectively, while the SPY returned +11.6% and -1.9%, respectively.

SEPN support price is $32.35 and resistance is $35.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SEPN shares will trade within this expected range on the day.